Chikashi Takeda, Executive Officer and CFO Nacho Abia, Executive Officer and COO PLAY LIST from the beginning Consolidated Financial Results for the 1st Quarter and Full-year Forecasts for Fiscal 2023 @ Highlights 01. Consolidated Financial Results and Business Review for the 1Q of Fiscal 2023 (FY Ending March 31, 2023) 1Q of Fiscal 2023 (1) Consolidated Financial Results 1Q of Fiscal 2023 (2) Endoscopic Solutions Division (ESD) 1Q of Fiscal 2023 (3) Therapeutic Solutions Division (TSD) 1Q of Fiscal 2023 (4) Scientific Solutions Division (SSD) Statement of Financial Position Consolidated Cash Flows 02. Forecasts for Fiscal 2023 Fiscal2023Consolidated Forecasts Fiscal2023Forecastsby Business Segment 03. TSD Growth Story TSD aims to grow by focusing on targeted diseases GI Endotherapyleverages its strong market position to derive high profits while improving the standard of care Urology delivering strong growth at high profitability through innovative solutions that improve workflow and clinical outcomes Respiratory EBUS scopes and needles are highly profitable, market leading solutions for lung cancer staging and diagnosis @ Appendix @ @ @ @ @ @ @ Q&A Q&A1 Q&A2 Q&A3 Q&A4 Q&A5 Q&A6 Q&A7 Back Next